{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:33:12Z","timestamp":1790065992028,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13555-021-00508-w","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T19:03:18Z","timestamp":1615316598000},"page":"599-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Randall","family":"Winnette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimanee","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"508_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pharmthera.2017.05.008","volume":"179","author":"G Skogberg","year":"2017","unstructured":"Skogberg G, Jackson S, \u00c5strand A. Mechanisms of tolerance and potential therapeutic interventions in alopecia areata. Pharmacol Ther. 2017;179:102\u201310.","journal-title":"Pharmacol Ther"},{"key":"508_CR2","doi-asserted-by":"publisher","first-page":"e015468","DOI":"10.1136\/bmjopen-2016-015468","volume":"7","author":"K Montgomery","year":"2017","unstructured":"Montgomery K, White C, Thompson A. A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia. BMJ Open. 2017;7:e015468.","journal-title":"BMJ Open"},{"key":"508_CR3","doi-asserted-by":"publisher","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985. (eCollection 2015)","DOI":"10.2147\/CCID.S53985"},{"issue":"4","key":"508_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/2229-5178.142483","volume":"5","author":"A Coondoo","year":"2014","unstructured":"Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416\u201325. https:\/\/doi.org\/10.4103\/2229-5178.142483.","journal-title":"Indian Dermatol Online J"},{"key":"508_CR5","unstructured":"Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. Draft guidance for industry, food and drug administration staff, and other stakeholders. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients-guidance-industry-food-and. Accessed 2 August 2020."},{"key":"508_CR6","unstructured":"Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/UCM193282.pdf. Accessed 2 August 2018."},{"key":"508_CR7","unstructured":"ePROVIDE. https:\/\/eprovide.mapi-trust.org\/. Accessed 12 September 2019."},{"key":"508_CR8","unstructured":"Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative: Alopecia Areata. Meeting date: September 11, 2017; report date: 2018. https:\/\/www.fda.gov\/media\/112100\/download. Accessed 21 February 2020."},{"key":"508_CR9","unstructured":"Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative: Alopecia Areata. Transcript date: September 11, 2017. https:\/\/www.fda.gov\/media\/110943\/download. Accessed 21 February 2020."},{"key":"508_CR10","volume-title":"Cognitive interviewing: a tool for improving questionnaire design","author":"GB Willis","year":"2001","unstructured":"Willis GB. Cognitive interviewing: a tool for improving questionnaire design. Thousand Oaks: Sage Publications; 2001."},{"issue":"3","key":"508_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"508_CR12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433\u201340.","journal-title":"Arch Dermatol"},{"key":"508_CR13","doi-asserted-by":"crossref","unstructured":"Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105\u201310.","DOI":"10.1177\/120347540100500202"},{"issue":"6","key":"508_CR14","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.jid.5700212","volume":"126","author":"TE Nijsten","year":"2006","unstructured":"Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol. 2006;126(6):1244\u201350.","journal-title":"J Invest Dermatol"},{"key":"508_CR15","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383."},{"key":"508_CR16","unstructured":"Ware JE Jr. The SF-36 health survey. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. 1996."},{"issue":"1","key":"508_CR17","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/jidsymp.2013.19","volume":"16","author":"TR Mendoza","year":"2013","unstructured":"Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc. 2013;16(1):S51\u20132.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"508_CR18","doi-asserted-by":"crossref","unstructured":"Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531\u20136.","DOI":"10.1684\/ejd.2012.1752"},{"issue":"3","key":"508_CR19","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1111\/j.1468-3083.2012.04629.x","volume":"27","author":"G Fabbrocini","year":"2013","unstructured":"Fabbrocini G, Panariello L, De Vita V, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276\u201381.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13555-021-00508-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T07:27:10Z","timestamp":1617348430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-021-00508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00508-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"21 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}